🔬Deep Research

AGIO — Agios Pharmaceuticals · catalysts, narrative & risks

·27 sourcesAGIO forecast →

Important framing

This is a point-in-time research snapshot as of 2026-10-03. Figures are drawn from the provided sources, which were published at different dates (July–October 2026 for the freshest data; 2024–2025 for older background). Nothing below is investment advice. Where sources conflict or use different definitions, I flag it.

Company and valuation snapshot (as of Oct 2, 2026)

Agios Pharmaceuticals (Nasdaq: AGIO) is a Cambridge, MA–based, commercial-stage biopharmaceutical company focused on rare diseases, particularly hemolytic anemias. Its lead product is mitapivat, marketed as Pyrukynd (PK deficiency) and Aqvesme (thalassemia) in the U.S. [2], [8], [23]. (Background/company history: [24]. Pipeline overview: [25], [27].)


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →